Impaired stem cell function of CD34+ cells selected by two different immunomagnetic beads systems

被引:0
作者
T Kimura
H Minamiguchi
J Wang
H Kaneko
H Nakagawa
H Fujii
Y Sonoda
机构
[1] Graduate School of Medical Science,Department of Molecular
[2] Kyoto Prefectural University of Medicine,Targeting Cancer Prevention, Division of Hematology and Oncology
[3] Shiga University of Medical Science,Second Department of Internal Medicine
[4] Graduate School of Medical Science,Department of Medicine, Division of Hematology and Oncology
[5] Kyoto Prefectural University of Medicine,Department of Hematology
[6] Kyoto First Red Cross Hospital,undefined
来源
Leukemia | 2004年 / 18卷
关键词
miniMACS; Isolex 50; CD34; cells; SCID-repopulating cell; transplantation;
D O I
暂无
中图分类号
学科分类号
摘要
We have been investigating the hematopoietic stem cell (HSC) activity of peripheral blood-derived CD34+ cells selected by two different laboratory immunomagnetic beads systems (MiniMACS and Isolex 50). In this study, the quality of purified CD34+ cells was directly compared using clonal cell culture, a cobblestone area-forming cell (CAFC) assay, and an in vivo severe combined immunodeficiency (SCID)-repopulating cell (SRC) assay. It was found that CD34+ cells selected by these two immunomagnetic methods showed a reduced yield of colony-forming cells and CAFCs compared with cells enriched by the StemSep device (a negative selection method). However, these CD34+ cells still showed significant SRC activity, including multilineage lymphomyeloid reconstitution. The percentage of human CD45+ cells in murine bone marrow after transplanting 5 × 105 CD34+ cells selected by the Isolex 50 was significantly lower than after transplanting cells selected by the MiniMACS or the StemSep. Our findings clearly demonstrated that CD34+ cells selected by the MiniMACS system had superior HSC functions, including SRC activity, compared with cells separated by the Isolex 50 system. More detailed functional analysis of immunomagnetically separated CD34+ cells may provide useful knowledge for basic research on HSCs as well as for clinical HSC transplantation.
引用
收藏
页码:566 / 574
页数:8
相关论文
共 203 条
[1]  
Krause DS(1996)CD34. Structure, biology, and clinical utility Blood 87 1-13
[2]  
Fackler MJ(2000)Clinical applications of CD34 Stem Cells 18 87-92
[3]  
Civin CI(1998) peripheral blood progenitor cells (PBPC) J Hematother 7 175-183
[4]  
May WS(1999)CD34 Br J Haematol 104 382-391
[5]  
Vogel W(1997) cell engraftment, Blood 89 337-344
[6]  
Scheding S(2000) expansion, and malignant cell depletion following immunomagnetic selection Exp Hematol 28 1187-1196
[7]  
Kanz L(2001)Autografting with CD34 Cytotherapy 3 285-294
[8]  
Brugger W(1995) peripheral blood stem cells: retained engrafment capability and reduced tumor cell content Blood 85 275-282
[9]  
Huntenburg CC(1996)Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction Blood 87 1687-1691
[10]  
Kunkel LA(2001)A prospective study of positive/negative Bone Marrow Transplant 28 849-857